Advertisement

Topics

Cambrex Company Profile

08:53 EDT 26th September 2017 | BioPortfolio

Cambrex Corporation (NYSE:CBM) provides products and services to accelerate the development and commercialization of branded and generic small molecule therapeutics. Cambrex supports its customers worldwide with R&D and cGMP manufacturing facilities in the US and Europe, an excellent regulatory compliance record and strong expertise in various chemical technologies. Pharmaceutical Products & Services Cambrex has built a comprehensive platform of chemical technologies for the synthesis of small molecule active pharmaceutical ingredients (APIs). We have extensive experience developing drug substances from early stage through clinical development, up to launch and commercial supply – from grams to tons. Cambrex has a broad range of services, which include: route selection, process development, analytical development, process scale-up, safety assessments and optimization. Our core technologies and offerings include: Highly Potent & Cytotoxic Compounds, High Energy, Hydrogenation, Biocatalysis/Biotransformation, Chiral Synthesis, Controlled Substances, Nitration and Polymeric Drug Delivery, including Taste Masking. Generic APIs For generic drug companies, Cambrex supplies more than 70 APIs (including controlled substances) for pain management, cardiovascular, gastrointestinal, central nervous system, endocrine and respiratory indications. Cambrex manufactures these products using complex chemistry and technical expertise while maintaining its long-standing reputation of quality and reliability. We work with generic drug companies well in advance of drug patent expiration, provide a non-infringing process and file a Drug Master File (DMF) for the generic active pharmaceutical ingredients.

Location

ONE MEADOWLANDS PLAZA,
EAST RUTHERFORD
New Jersey
07073
United States of America

Contact

Phone: 201 804 3000
Email: pharma@cambrex.com


News Articles [39 Associated News Articles listed on BioPortfolio]

Cambrex to Present at UBS 22nd Annual Global Healthcare Services Conference

EAST RUTHERFORD, N.J., Feb. 6, 2012 /PRNewswire/ -- Cambrex Corporation (NYSE: CBM, "Cambrex") is pleased to announce that Greg Sargen, Executive Vice President and Chief Financial Officer, will ...

Cambrex investing $24m in API manufacturing capabilities

Cambrex Corporation is investing $24m in a new facility to manufacture highly potent APIs (HPAPIs).

Cambrex invests $2.4m at former PharmaCore site

Cambrex Corporation is installing a fourth reactor suite at its High Point, NC-based facility as it continues to grow with its customers in the market, says company VP at CPhI North America.

Cambrex continues to up capacity with more than $200m invested in 5 years

Cambrex Corporation has increased new capacity at its Sweden-based cGMP as the manufacturer focuses on market demand and customer need, says VP.

Cambrex sees Q2 revs and earnings rise, confirms interest in takeovers

Cambrex Corporation says higher demand for APIs for controlled substances and branded drugs drove Q2 growth and confirms it is on the lookout for acquisitions. 

Cambrex announces investment and expansion in Sweden

Cambrex, manufacturer of small molecule active pharmaceutical ingredients (APIs), has announced it is investing in new capacity and continuous flow technology at its Karlskoga facility in Sweden.

Cambrex Invests $2.4M in API Capacity at NC Facility

NewsCambrex invests to increase pilot scale API capacity at its High Point, NC facility.Contributed Author: 

Cambrex adding $3.2m analytical lab at NC facility

Cambrex Corporation is adding a new $3.2m, 11,000 square foot analytical laboratory to its High Point, NC-based facility.

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

Cambrex Corporation

Cambrex provides products and services to accelerate the development and commercialization of small molecule therapeutics including APIs, advanced intermediates, enhanced drug delivery, and other prod...

Cambrex

Cambrex Corporation (NYSE:CBM) provides products and services to accelerate the development and commercialization of branded and generic small molecule therapeutics. Cambrex supports its customers wor...

More Information about "Cambrex" on BioPortfolio

We have published hundreds of Cambrex news stories on BioPortfolio along with dozens of Cambrex Clinical Trials and PubMed Articles about Cambrex for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cambrex Companies in our database. You can also find out about relevant Cambrex Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topic

Generics Drugs
A generic drug (generic drugs, short: generics) is a drug defined as "a drug product that is comparable to brand/reference listed drug product in dosage form, strength, route of administration, quality and performance characteristics, and intended u...


Corporate Database Quicklinks



Searches Linking to this Company Record